The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe clinical effectiveness and costeffectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Rapid reviews are completed in a limited time to inform the appraisal and guideline development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidelines produced by NICE are informed by a wide range of sources.The research reported in this monograph was funded as project number 00/17/01.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research ...

Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR

“…[57][58][59][60] Although several studies have reported adherence to SSRIs for the treatment of depression, 61,62 none have evaluated adherence to bupropion SR, and a recent meta-analysis of the smoking cessation pharmacotherapy literature did not address the issue. 63 A better understanding of the predictors, including genotype, of nonadherence to bupropion therapy is needed. The fact that, in the present study, female carriers of the A1 allele were more likely to stop taking bupropion due to side effects suggests that efforts to better understand the biological contributors to nonadherence should begin with these individuals.…”

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

“…Using data from two randomized pharmacogenetic trials of tobacco dependence treatment, we have estimated the potential effect on treatment costs and long-term survival of using genetic testing to choose between TN and bupropion for individual smokers. Our approach differs from the previous cost-effectiveness analyses of tobacco dependence treatment [30][31][32][33][34][35][36] in the following ways: (i) we consider Under all parameter combinations that we considered, non-tailored varenicline was the most effective (and expensive) admissible treatment. Bupropion was dominated only in the best-case scenario.…”

“…Although others have investigated the cost-effectiveness of pharmacologic smoking-cessation interventions, [30][31][32][33][34][35][36][37] we are the first to include a pharmacogenetic tailoring arm in such an evaluation. These previous studies have suggested that pharmacotherapy is cost-effective compared to no treatment or counseling alone, with ICERs in the range of $800-$1200 per quitter and $900-$11 200 per LY, depending on the regimen and the age and sex of the smoker.…”

A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation

“…Previous literature reviews Woolacott et al, 2002) (2002), we considered two scenarios for the control 12-month cessation probability, p CON . We assumed a 1% spontaneous annual quit rate, plus an additional 5.1% using brief advice (3-10 min) as the comparator or an additional 11.2% using more intensive individual counseling (>10 min) as the comparator (Nielsen & Fiore, 2000).…”